Trials Sponsors Conditions Drugs Pricing

Conditions

Breast Cancer Colorectal Cancer Kidney Cancer Liver Cancer Lung Cancer Nasopharyngeal Cancer

Outcome Measures

Primary Outcomes (1)

OS and PFS
Overall survival and progression-free survival
The enrollment period was 3 years and the follow-up period was 5 years

Secondary Outcomes (1)

ORR, CR+PR
The enrollment period was 3 years and the follow-up period was 5 years

Study Arms (1)

DC-CIK

EXPERIMENTAL

Other: CELL

Interventions

CELLOther

inject the DC-CIK(dendritic cell activated and cytokine induced killer cell)

DC-CIK

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 75 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

(1) Patients diagnosed with liver cancer, renal clear cell carcinoma, nasopharyngeal carcinoma, lung cancer, colorectal cancer, breast cancer and nasopharyngeal carcinoma by imaging examination, tissue and/or cytology, and patients after conventional treatment (surgery, chemotherapy and radiotherapy); (2) No history of other tumors (except surgically cured skin squamous cell carcinoma).

Sponsors & Collaborators

Sun Yat-sen University
Otherlead

Study Sites (1)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China

RECRUITING

Yan TangCONTACT02087343404

MeSH Terms

Conditions

Liver NeoplasmsKidney NeoplasmsNasopharyngeal NeoplasmsLung NeoplasmsColorectal NeoplasmsBreast Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesLiver DiseasesUrologic NeoplasmsUrogenital NeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy Complications

Study Officials

Jianchuan Xia
Sun Yat-sen University
STUDY DIRECTOR

Central Study Contacts

Jianchuan Xia, doctor

CONTACT

02087343404

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: professor

Study Record Dates

First Submitted

July 10, 2020

First Posted

July 20, 2020

Study Start

May 6, 2016

Actual (reported)

Primary Completion

December 31, 2021

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

DC-CIK

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

DC-CIK

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations